TP53 and neoplasm: TP53 mutations, which are linked to more aggressive tumor behavior, are associated with a higher likelihood of visceral metastases, particularly in the liver and brain, due to the loss of tumor suppressor function and increased genomic instability, with a prevalence of approximately 20–30% in patients with metastatic breast cancer [92].